The purpose of this study is to investigate the efficacy, safety, tolerability of MN-166 compared to a placebo, for the treatment of ALS.  

The study is expected to take about a year to complete, but participants will be given an option to continue in the study for another 6 months. 

Participants are volunteering their time and are free to withdraw at any point during the study.

To be eligible, you must be 18 to 80 years of age, with a diagnosis of ALS.

ClinicalTrials.gov Identifier: NCT04057898

The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS   

The study is expected to take about a year to complete

Participants volunteer their time and can withdraw at any point during the study.

To be eligible, you must be 18 to 80 years of age, with a diagnosis of ALS.

ClinicalTrials.gov Identifier: NCT05633459